Clinical Trials Logo

Clinical Trial Summary

To assess the safety and tolerability of HRS2543 in patients with advanced tumors and to determine the recommended phase II dose (RP2D) of HRS2543


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05068856
Study type Interventional
Source Shanghai Hengrui Pharmaceutical Co., Ltd.
Contact Jie Xie, M.M.
Phone +021-61053363
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date September 30, 2021
Completion date August 31, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02419417 - Study of BMS-986158 in Subjects With Select Advanced Cancers Phase 1/Phase 2
Recruiting NCT04808453 - Phase I Study of CPI-300 in Patients With Advanced Tumors Phase 1
Recruiting NCT04198818 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors Phase 1/Phase 2
Not yet recruiting NCT04151810 - Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT03781362 - Study of CPI-100 in Patients With Advanced Tumors Phase 1
Recruiting NCT03908814 - Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors Phase 1
Recruiting NCT05061628 - The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor Phase 1
Recruiting NCT03444714 - Phase I Study of RiMO-301 With Radiation in Advanced Tumors Phase 1